Dyne: Accelerated Approval Established Endpoint Sets Stage For DM1 Data In Mid-2026 [Seeking Alpha]
Dyne Therapeutics, Inc. (DYN)
Last dyne therapeutics, inc. earnings: 11/1 04:30 pm
Check Earnings Report
US:NYSE Investor Relations:
dynegy.com/investors/presentations-events
Company Research
Source: Seeking Alpha
The pipeline includes zeleciment rostudirsen for DMD exon 51 skipping patients, with registrational cohort data expected in late 2025 and a potential BLA in early 2026. With strong cash runway and multiple near-term catalysts, I maintain a "Strong Buy" rating on Dyne Therapeutics, citing significant upside if clinical milestones are met. Looking for a portfolio of ideas like this one? Members of Biotech Analysis Central get exclusive access to our subscriber-only portfolios. Learn More » Nansan Houn/iStock via Getty Images The last time I wrote about Dyne Therapeutics ( NASDAQ: DYN ) it was with respect to a Seeking Alpha article entitled " Dyne: Accelerated Approval Of DYNE-101 Might Be Possible With Surrogate Biomarker ". With More on my IG service This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering
Show less
Read more
Impact Snapshot
Event Time:
DYN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DYN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DYN alerts
High impacting Dyne Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
DYN
News
- Bernstein Sees Favorable Risk-Reward for Dyne Therapeutics (DYN) Ahead of Major DYN-251 Data Release [Yahoo! Finance]Yahoo! Finance
- Dyne Therapeutics (NASDAQ:DYN) had its "market perform" rating reaffirmed by analysts at Sanford C. Bernstein.MarketBeat
- Dyne Therapeutics (NASDAQ:DYN) had its price target lowered by analysts at JPMorgan Chase & Co. from $18.00 to $17.00. They now have a "neutral" rating on the stock.MarketBeat
- Dyne Therapeutics (NASDAQ:DYN) had its price target lowered by analysts at Oppenheimer Holdings, Inc. from $13.00 to $11.00. They now have a "market perform" rating on the stock.MarketBeat
- Dyne Therapeutics (NASDAQ:DYN) had its "outperform" rating reaffirmed by analysts at Evercore ISI.MarketBeat
DYN
Earnings
- 5/8/25 - Miss
DYN
Sec Filings
- 11/14/25 - Form SCHEDULE
- 11/14/25 - Form SCHEDULE
- 11/5/25 - Form 8-K
- DYN's page on the SEC website